Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06388551
Other study ID # LY03017/CT-CHN-101
Secondary ID
Status Not yet recruiting
Phase Phase 1
First received
Last updated
Start date May 10, 2024
Est. completion date March 30, 2025

Study information

Verified date April 2024
Source Luye Pharma Group Ltd.
Contact Huafang Li
Phone +8618017311256
Email lhlh_5@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1,randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 60
Est. completion date March 30, 2025
Est. primary completion date March 30, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - Subject who voluntarily participate and sign the informed consent form. - Healthy male/female volunteers aged =18 and = 45 years. - Body weight = 50.0 kg for men and = 45.0 kg for women, and body mass index (BMI) =18.5 and < 26.0 kg/m2. - Able to comply with the lifestyle restrictions. Exclusion Criteria: - Subject has a history of allergy to any component of the investigational drug or similar drugs, or allergic constitution. - Subject has a current or past medical history that may affect the clinical trial or dysfunction, including but not limited to the past or current respiratory system, circulatory system, digestive system, urinary system, reproductive system, nervous system, endocrine system, immune system, motor system, blood system, psychiatry/ psychology, dermatology and other clinically serious diseases or chronic diseases; or any other diseases that may interfere with the test results. - Any surgical condition or condition may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects. - Subject has a history of surgery within 3 months prior to administration, or failure to recover from surgery, or having an expected surgical plan during the trial. - Subject has abnormal vital signs, laboratory abnormalities, and ECGs. - Subject has used any of over-the-counter products within 7 days or prescription medications within 28 days prior to dosing. - Subject positive for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), HIV antibody (HIV-Ab), or syphilis seroreactivity (Trust). - Subject has a history of alcohol abuse within 1 year or positive alcohol breath test results. - Subject has a history of substance abuse within 1 year or a positive urine drug screen. - Subject who has daily smoking of = 5 cigarettes within 3 months. - Subject who has special requirements for food, cannot comply with the unified diet or have dysphagia. - Subject who has consumption of special diet (such as grapefruit, chocolate, coffee, xanthine-rich foods/drinks) within 48 hours prior to dosing and/or subject who has excessive daily consumption of tea, coffee, grapefruit juice, caffeinated beverages for nearly 3 months. - Subject who has participated in other clinical trials within 3 months before administration. - Subject has used blood products or being blood donor or blood loss within 3 months. - Pregnant, lactating women, or positive pregnancy test. - Subject who refusal to contraception, or plan to donate sperm or ovums. - Subject who has a history of needle or blood faintness. - Subject directly involved in this clinical trial. - Poor compliance or other conditions which would make participation in the study unsuitable.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
LY03017
single dose, administered orally
LY03017-Placebo
single dose, administered orally

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Luye Pharma Group Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) up to 216 hours
Secondary Maximum observed concentration (Cmax) of LPM526000133 in plasma up to 216 hours
Secondary Time to maximum observed concentration (Tmax) of LPM526000133 in plasma up to 216 hours
Secondary The area under the concentration-time curve from time zero extrapolated to infinity (AUC0-8) of LPM526000133 in plasma up to 216 hours
Secondary Area under the concentration-time curve from time zero to the time of last quantifiable concentration (AUC[0-last]) of LPM526000133 in plasma up to 216 hours
Secondary Apparent terminal elimination half-life (t1/2) of LPM526000133 in plasma up to 216 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05985993 - Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia N/A
Withdrawn NCT01234298 - SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia Phase 3
Completed NCT03397134 - Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia Phase 3
Recruiting NCT04620460 - Efficacy and Mechanisms of Low-intensity Focused Ultrasound on Negative Symptoms in Patients With Schizophrenia N/A